Camlipixant

WITHDRAWN · PHASE1 · Cough

The study has been withdrawn given the recent decision to cease further development of camlipixant in refractory chronic cough (RCC) based on Phase 3 program results.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.